

# Alexandru E Eniu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/797553/publications.pdf>

Version: 2024-02-01

58  
papers

3,906  
citations

218677

26  
h-index

175258

52  
g-index

59  
all docs

59  
docs citations

59  
times ranked

6572  
citing authors

#	ARTICLE	IF	CITATIONS
1	ESO's career development program (2002-2021): Presentation and evaluation. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103576.	4.4	0
2	Changing the landscape of European School of Oncologyâ€“European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic. <i>Future Oncology</i> , 2022, 18, 2857-2864.	2.4	1
3	ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. <i>Journal of Cancer Education</i> , 2021, 36, 556-560.	1.3	5
4	Why is appropriate healthcare inaccessible for many European breast cancer patients? â€“ The EBCC 12 manifesto. <i>Breast</i> , 2021, 55, 128-135.	2.2	18
5	Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 631-640.	2.5	11
6	The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resourceâ€“Stratified Phased Implementation: Methods and overview. <i>Cancer</i> , 2020, 126, 2339-2352.	4.1	54
7	Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 105-124.	329.8	123
8	Breast cancer treatment: A phased approach to implementation. <i>Cancer</i> , 2020, 126, 2365-2378.	4.1	74
9	Recommendations from the ASCO Academic Global Oncology Task Force. <i>JCO Global Oncology</i> , 2020, 6, 1666-1673.	1.8	8
10	Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?. <i>ESMO Open</i> , 2019, 4, e000483.	4.5	31
11	Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe. <i>Oncologist</i> , 2019, 24, e30-e37.	3.7	19
12	Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. <i>Breast Care</i> , 2019, 14, 373-381.	1.4	8
13	Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1013-1013.	1.6	26
14	Global cancer control: responding to the growing burden, rising costs and inequalities in access. <i>ESMO Open</i> , 2018, 3, e000285.	4.5	169
15	Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. <i>European Journal of Cancer</i> , 2018, 89, 27-35.	2.8	172
16	Access to Affordable Breast Cancer Care in Eastern Europe. <i>Current Breast Cancer Reports</i> , 2018, 10, 170-178.	1.0	4
17	Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning. <i>European Journal of Cancer</i> , 2018, 104, 127-136.	2.8	23
18	Aberrant miRNAs expressed in HER-2 negative breast cancers patient. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 257.	8.6	46

#	ARTICLE	IF	CITATIONS
19	PARP Inhibitors in Breast Cancer: Why, How, and When?. <i>Breast Care</i> , 2018, 13, 216-219.	1.4	4
20	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. <i>Lancet Oncology</i> , The, 2017, 18, 917-928.	10.7	93
21	Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer. <i>Breast Care</i> , 2017, 12, 152-158.	1.4	14
22	Shortage of Drugs: Solutions. <i>Breast</i> , 2017, 36, S28-S29.	2.2	0
23	The global burden of women's cancers: a grand challenge in global health. <i>Lancet</i> , The, 2017, 389, 847-860.	13.7	666
24	Changing global policy to deliver safe, equitable, and affordable care for women's cancers. <i>Lancet</i> , The, 2017, 389, 871-880.	13.7	66
25	Cancer Care and Control as a Human Right: Recognizing Global Oncology as an Academic Field. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 409-415.	3.8	11
26	Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 510-510.	1.6	10
27	BRCA 1/2 mutations by next-generation sequencing testing in 200 Romanian high-risk patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e13116-e13116.	1.6	1
28	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016, 1, e000107.	4.5	11
29	Back to the "essence" of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines. <i>ESMO Open</i> , 2016, 1, e000030.	4.5	10
30	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
31	Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. <i>ESMO Open</i> , 2016, 1, e000142.	4.5	95
32	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1230-1239.	10.7	55
33	Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. <i>Oncologist</i> , 2016, 21, 1183-1190.	3.7	37
34	ESMO and WHO: 14 years of working in partnership on cancer control. <i>ESMO Open</i> , 2016, 1, e000012.	4.5	4
35	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. <i>Journal of Clinical Oncology</i> , 2016, 34, 3400-3408.	1.6	65
36	<sc>PDGF</sc> beta targeting in cervical cancer cells suggest a fine-tuning of compensatory signalling pathways to sustain tumourigenic stimulation. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 371-382.	3.6	8

#	ARTICLE	IF	CITATIONS
37	ecancermedalscience. Ecancermedalscience, 2014, 8, 463.	1.1	26
38	Differential Peripheral Blood Gene Expression Profile Based on Her2 Expression on Primary Tumors of Breast Cancer Patients. PLoS ONE, 2014, 9, e102764.	2.5	10
39	Morphologic and molecular subtype status of individual tumor foci in multiple breast carcinoma. A study of 155 cases with analysis of 463 tumor foci. Human Pathology, 2014, 45, 409-416.	2.0	13
40	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncology, The, 2014, 15, 1137-1146.	10.7	382
41	Supportive and palliative care for metastatic breast cancer: Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast, 2013, 22, 616-627.	2.2	49
42	A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel. Journal of Cardiovascular Pharmacology, 2013, 61, 495-504.	1.9	4
43	Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.. , 2013, , .		0
44	Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid. Clinical Cancer Research, 2012, 18, 4841-4849.	7.0	124
45	A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer. Cancer Investigation, 2012, 30, 309-316.	1.3	11
46	Breast cancer management in low resource countries (LRCs): Consensus statement from the Breast Health Global Initiative. Breast, 2011, 20, S3-S11.	2.2	154
47	Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wiener Klinische Wochenschrift, 2010, 122, 368-379.	1.9	7
48	Best of breast cancer " ASCO 2009. Memo - Magazine of European Medical Oncology, 2009, 2, 223-227.	0.5	0
49	Breast pathology guideline implementation in low- and middle-income countries. Cancer, 2008, 113, 2297-2304.	4.1	48
50	Locally advanced breast cancer. Cancer, 2008, 113, 2315-2324.	4.1	45
51	Effective but cost-prohibitive drugs in breast cancer treatment. Cancer, 2008, 113, 2353-2358.	4.1	16
52	Guideline implementation for breast healthcare in low- and middle-income countries: Treatment resource allocation. Cancer, 2008, 113, 2269-2281.	4.1	75
53	A Pilot Project to Develop Checklist-Based Recommendations on the Requirements for Clinical Cancer Research Centers in Countries with Limited Resources. Breast Care, 2008, 3, 33-35.	1.4	0
54	The Breast Health Global Initiative: A Framework for Improving Breast Health Care in Limited-Resource Countries. Breast Diseases, 2007, 17, 314-317.	0.0	0

#	ARTICLE	IF	CITATIONS
55	Breast Cancer in Limited-Resource Countries: An Overview of the Breast Health Global Initiative 2005 Guidelines. Breast Journal, 2006, 12, S3-S15.	1.0	285
56	Breast Cancer in Limited-Resource Countries: Treatment and Allocation of Resources. Breast Journal, 2006, 12, S38-S53.	1.0	68
57	Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer. Oncologist, 2005, 10, 665-685.	3.7	86
58	Treatment of Breast Cancer in Countries with Limited Resources. Breast Journal, 2003, 9, S67-S74.	1.0	58